At the news
? NEUTRALIMPACT 2/10 144 filed Nov 5, 2026 at 16:28 ET
Progyny CEO Peter Anevski filed a Form 144 notice of intent to sell 90,000 shares of common stock, with an approximate market value of $2.71 million based on the filing. The shares were acquired through vesting of restricted stock units, performance stock units, and employee stock purchase plan grants from 2022 to early 2026. This is a routine insider sale of vested equity awards, not a secondary offering or open-market purchase.
- Insider: Peter Anevski, CEO and Director of Progyny, Inc.
- Shares to be sold: 90,000 shares of common stock
- Approximate value: $2,709,000 (based on filing date price of $30.10 per share)
- Shares acquired via vesting of RSUs, PSUs, and ESPP from 1/1/2022 to 3/3/2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access